|
|
||||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the Department of Pulmonary and Critical Care Medicine, Memorial Hospital of Rhode Island and Brown Medical School, Providence, RI.
Correspondence to: Annie Lin Parker, MD, FCCP, Department of Pulmonary and Critical Care Medicine, Memorial Hospital of Rhode Island, 111 Brewster St, Pawtucket, RI 02860; e-mail: Annie_Parker{at}brown.edu
| Abstract |
|---|
|
|
|---|
Study design: Data analysis of consecutive subjects who had a
20% reduction in FEV1 after
189 cumulative units of methacholine over a 7-year period.
Setting: Pulmonary function laboratory in a university-affiliated hospital.
Patients: A total of 764 consecutive subjects aged 4 to 91 years (mean ± SD age, 40.8 ± 19.6 years). There were 223 male (29.3%) and 540 female (70.7%) subjects.
Measurements and results: Airway reactivity was assessed as the dose-response slope of the reduction in FEV1 from baseline vs the cumulative dose of inhaled methacholine. The cumulative dose of methacholine causing 20% reduction in FEV1 (PD20) was used as the indicator of airway sensitivity. In a linear regression model that included age, height, and percentage of predicted FEV1, the FEF2575/FVC ratio accounted for 7.6% of variability in airway reactivity (p < 0.0001, r2 = 0.076). Subjects with higher airway sensitivity, indicated by lower PD20, also had a lower FEF2575/FVC ratio.
Conclusions: A low FEF2575/FVC ratio, indicating small airway size relative to lung size, is associated with higher airway sensitivity and reactivity to methacholine in susceptible subjects.
Key Words: airway reactivity airway sensitivity dysanapsis methacholine
| Introduction |
|---|
|
|
|---|
The current study was designed to assess the relationship of FEF2575/FVC ratio and methacholine airway responsiveness over a broader range of ages and in a group that included women and children. The airway responsiveness to methacholine was characterized by the following: (1) reactivity, as assessed by the slopes of the methacholine dose-response curve; and (2) sensitivity, expressed by the cumulative dose of methacholine required to cause 20% reduction in FEV1 (PD20).9
| Materials and Methods |
|---|
|
|
|---|
20% reduction in FEV1 after
189 cumulative units (cu) of methacholine between January 1993 and September 2000 were included in the study. Only subjects with known interstitial lung diseases, neuromuscular diseases, and diaphragm paralysis were excluded. All studies were performed in the Pulmonary Function Laboratory of Memorial Hospital of Rhode Island.
Pulmonary Function Testing
Spirometry was performed using standard techniques on the spirometer (Transfer Test Model C Apparatus; Morgan Scientific; Haverhill, MA). At least three spirograms were performed until the American Thoracic Society standard for acceptability and reproducibility of the FVC maneuver was met.10
The spirogram with the highest value for FVC was used as the baseline FVC, and the spirogram with the highest FEV1 was used as the baseline FEV1. All other baseline measurement were obtained from the spirogram with the highest sum of FVC and FEV1.10
Following spirometry, lung volumes and specific airways conductance were determined by variable-pressure body plethysmography (Warren E. Collins; Braintree, MA).10
11
The pulmonary function test (PFT) data were expressed as a percentage of predicted normal values.12
13
Methacholine Bronchoprovocation Protocol
Serial dilutions of methacholine chloride (Provocholine; Methapharm; Branford, ON, Canada) were prepared in normal saline solution containing 0.4% phenol (pH 7.0) and passed through bacterial-retentive filters with 0.2 µm porosity. Methacholine aerosol was delivered using a Rosenthal French Nebulization Dosimeter (Laboratory for Applied Immunology; Baltimore, MD) and a DeVilbiss Nebulizer (DeVilbiss; Somerset, PA) set for a 0.6-s delivery time with an output of 7.4 L per actuation. All testing was done with the same equipment by the same two technicians. Following a control inhalation of diluent, each patient took five slow inhalations from functional residual capacity to total lung capacity from the dosimeter starting at a concentration of 0.025 mg/mL. A FVC maneuver was performed within 5 min of methacholine inhalation. If the reduction in FEV1 was < 20% from baseline, five inhalations of increasing concentrations of methacholine, 0.25 mg/mL, 2.5 mg/mL, 10 mg/mL, and 25 mg/mL, were administered. The time between administration of different concentrations was < 3 min. The corresponding totals were 0.125 cu, 1.4 cu, 14 cu, 64 cu, and 189 cu, with one dose unit being one inhalation of 1 mg/mL. The study was terminated when FEV1 fell by
20% at any concentration or when the maximum dose of methacholine (189 cu) had been administered.
Data Analysis
Airway reactivity was analyzed as a continuous variable using the slope of the dose-response curve. The dose-response slope (DRS) was defined as the reduction in FEV1 from baseline after the final dose of methacholine inhaled divided by the cumulative dose inhaled. The DRS was expressed in units of the percentage reduction in FEV1 per micromole methacholine. Because of their highly skewed distribution, DRS was logarithmically transformed (log10) for all analysis. A small constant (0.3) was added to each value of DRS to eliminate zero and slightly negative values.7
14
A simple linear regression model was constructed for FEF2575/FVC ratio and airway reactivity (log10DRS) with log10DRS as the dependent variable.
In another analysis, a multiple linear regression model with log10DRS as the dependent variable was created to include age, height, and FEV1 percentage predicted and a coefficient of determination (r2) was obtained. The FEF2575/FVC ratio was then added to this model, and a new r2 was obtained. The difference in these two coefficients (r2) was considered the explaining power of the FEF2575/FVC ratio for the variability in methacholine airway reactivity, independent of age, height, and FEV1. The analyses were then repeated for both genders and four different age groups (
25, > 25 to
45, > 45 to
65, and > 65 years).
Airway sensitivity was assessed by the PD20. Subjects were classified into four groups based on PD20:
1.4 cu, > 1.4 to
14 cu, > 14 to
64 cu, and > 64 to
189 cu. The cumulative unit cut-off for each group corresponded to the increments of methacholine concentration used in our protocol. Differences in FEF2575/FVC ratio among groups were determined by using analysis of variance and the Fisher least-significant difference multiple-comparison test. Differences were considered significant for p < 0.05. All analyses were performed using Statview (SAS Institute; Cary, NC).
| Results |
|---|
|
|
|---|
|
0.70 (Table 2
).
|
25 years, 0.80 ± 0.23 for age > 25 to
45 years, 0.68 ± 0.24 for age > 45 and to
65 years, and 0.55 ± 0.23 for age > 65 years). Male subjects consistently had a lower FEF2575/FVC ratio than female subjects in every age group. The association between FEF2575/FVC ratio and airway reactivity remained significant in all age groups, with r2 ranging from 0.052 to 0.136 (Table 3 ). Because the smoking status of the subjects was not available, the analysis was not done for smokers vs nonsmokers.
|
When subjects were grouped according to their airway sensitivity as measured by PD20, there were significant differences in FEF2575/FVC ratios among the groups (Table 4
). Subjects with lower PD20 values, indicating higher airway sensitivity to methacholine, had lower FEF2575/FVC ratios. When subjects were classified into four quartiles according to their FEF2575/FVC ratios with similar numbers of patients in each quartile, subjects in the quartile with the lowest FEF2575/FVC ratio had significantly lower PD20 values compared to subjects in the other three quartiles (all p
0.0001) [Fig 1
]. There was a significant correlation between airway reactivity and sensitivity to methacholine when analysis was made of log10DRS and PD20 (r = 0.79, p < 0.0001).
|
|
| Discussion |
|---|
|
|
|---|
Airway hyperresponsiveness is considered one of the characteristics of asthma.1 Even though it can be demonstrated in asymptomatic, nonasthmatic subjects, there is evidence that airway hyperresponsiveness may precede the symptoms and clinical diagnosis of asthma in both children and adults.15 16 17 These findings suggest that airway hyperresponsiveness may play a role in the pathogenesis of asthma. Identifying pulmonary function characteristics that are associated with airway hyperresponsiveness may provide a better understanding of mechanisms that predispose an individual to asthma. Our findings that the FEF2575/FVC ratio was significantly associated with airway reactivity and sensitivity suggest that small airways relative to lung size may be a feature that promotes asthma.
Airway responsiveness to methacholine is often analyzed in the construct of airway sensitivity and reactivity. Airway sensitivity can be quantified by the threshold dose of methacholine that leads to a predetermined level of airway narrowing. Factors that can affect airway sensitivity may include intrinsic properties of the airway smooth muscle, the sympathetic and parasympathetic tones, and the level of airway inflammation. Once airway narrowing has been triggered, further airway narrowing may occur in response to a higher dose of methacholine. Airway reactivity represents the degree of further narrowing and can be quantified as the slope of the relationship between the cumulative dose of methacholine and the decrement of FEV1. Airway reactivity may depend on factors such as synthesis of prostaglandins18 and stimulation of airway irritant receptors19 and may be independent of factors that affect airway sensitivity. For example, ß-adrenergic blockade changes the threshold, but not the slope of the dose-response curves to acetylcholine.20
The association between airway size and hyperresponsiveness has been explored.7 21 22 Britton and colleagues21 measured airway reactivity to methacholine in a large, random population sample of adults between the ages of 18 years and 70 years. They demonstrated that at any given age, airway caliber as indicated by the baseline FEV1, in absolute terms or as percentage of predicted, and atopy were the major determinants of airway hyperreactivity in the general population. Kanner et al22 found a similar association between FEV1 and airway hyperresponsiveness to methacholine in a group of smokers between ages of 35 years and 60 years with mild COPD. The positive association between FEV1 percentage of predicted and log10DRS in our study is consistent with these findings.
We chose to further analyze the association between airway size and reactivity by considering airway size relative to lung size. Green and colleagues4
proposed that there were substantial between-individual differences in airway size independent of lung parenchymal size. These differences may have an embryologic basis reflecting physiologically normal but disproportionate growth of the airways and parenchyma within the lung. They termed this phenomenon dysanapsis and speculated that differences in the airway-parenchymal relationship might influence the pathogenesis of airway diseases. Mead5
subsequently showed that dysanapsis manifested itself by an inverse relationship between vital capacity (VC) and the product of the ratio of maximal flow at 50% of VC (
max50) divided by VC and the static recoil pressure of the lung at 50% of VC (Pst[L]50) [
max50/VC x Pst[L]50]. A low (
max50/VC x Pst[L]50)/VC ratio would indicate smaller airways relative to the lung parenchyma. A less invasive measure of dysanapsis is the FEF2575/FVC ratio.4
5
6
A major advantage of using the FEF2575/FVC ratio is that both parameters can be derived from a maximal expiratory flow-volume loop.
The relationship between the FEF2575/FVC ratio and airway reactivity has been investigated. Litonjua et al7 found that the FEF2575/FVC ratio was negatively associated with the degree of methacholine airway responsiveness (as assessed by the slope of the log10 dose and FEV1 relationship) in a group of 929 middle-aged and older men (average age, 60.5 ± 7.7 years; range, 41 to 86 years). In their study, FEF2575/FVC ratio explained approximately 5.1% of the variability of log10DRS. They concluded that individuals with small airways relative to lung size may be more likely to have hyperresponsive airways than those without dysanapsis.
We extended the findings of Litonjua et al7 to a group of subjects that included female subjects and younger adults. We confirmed their findings that the FEF2575/FVC ratio is a determinant of airway reactivity to methacholine. In both studies, despite the difference in subject population, the coefficients of determination were in the similar range (5.1% vs 7.6%). We also found that the FEF2575/FVC ratio is a stronger determinant of airway reactivity than FEV1. The r2 value for FEF2575/FVC ratio was greater than the r2 for FEV1 in simple regression models (0.058 vs 0.038). Given the expected strong correlation between FEF2575 and FEF2575/FVC ratio, one may expect the same result for FEF2575. Indeed, a significant association was also noted between FEF2575 and airway reactivity. However, in a multiple linear regression model that included age, height, FEV1, FEF2575, and FEF2575/FVC ratio with log10DRS as the dependent variable, only FEF2575/FVC ratio had a significant p value. These findings suggest that the airway size relative to lung size is a more important determinant of airway reactivity than the absolute size of the airway.
Another characteristic of the airway response to various triggers is airway sensitivity. We assessed airway sensitivity as the PD20. When subjects were classified into four groups according to their PD20, those with lower PD20 had lower FEF2575/FVC ratio. Similarly, when subjects were classified into four groups according to their FEF2575/FVC ratio, subjects with the lowest ratio also had the lowest PD20. Both findings support the notion that subjects who were more sensitive to methacholine have smaller airway size relative to their lung size.
Dysanapsis between airway size and lung size may have an embryologic basis,4 but acquired factors such as smoking or inflammation that affect the airway wall thickness may alter the relationship between airway and lung size and lower the FEF2575/FVC ratio. We did not control for the history of smoking or the level of airway inflammation because these data were not available; however, Litonjua and colleagues7 have found that the association between FEF2575/FVC ratio and methacholine airway responsiveness was not affected by the pack-years of smoking, eosinophil counts, or IgE measurements. These findings suggest that dysanapsis in the form of small airway size relative to lung size, either intrinsic or acquired, will lead to higher airway reactivity and sensitivity to methacholine.
Epidemiologic data on asthma prevalence have demonstrated a gender difference that varies with age. Asthma and wheezing are more prevalent in boys than in girls.23 24 During puberty, there is a gender reversal in the prevalence25 26 ; after puberty, women have a higher prevalence and morbidity rate of asthma than men.8 27 Gender differences in the rate of lung growth and in airway size have been suggested as one of the potential explanations for this phenomenon.28 Female infants have proportionately larger airways relative to their lung size than do male infants.29 During childhood and adolescence, the growth of airway, relative to lung parenchyma, occurs faster in teenage boys than in teenage girls.30 31 These findings suggest that smaller airways may have a role in the higher prevalence of asthma and wheezing in prepubertal boys; the subsequent faster growth of airways in adolescent male compared to female subjects may partly explain the gender reversal of asthma prevalence after puberty. Male subjects in our study had a lower FEF2575/FVC ratio than female subjects in all age groups. Our subjects were a preselected group who were symptomatic with airway hyperresponsiveness; therefore, the results of persistently lower FEF2575/FVC ratio in male subjects cannot be generalized to a general population. However, the fact that the association of lower FEF2575/FVC ratios with higher airway reactivity and sensitivity exist in both genders and in all age groups suggests that the association between dysanapsis and airway hyperreactivity may be the potential link between anatomic variations and the clinical development of asthma.
We conclude that FEF2575/FVC ratio is a determinant of airway responsiveness to methacholine. A low FEF2575/FVC ratio, indicating small airway size relative to lung size, is associated with higher airway sensitivity and reactivity to methacholine in susceptible subjects.
| Acknowledgements |
|---|
| Footnotes |
|---|
max50 = maximal flow at 50% of vital capacity Received for publication November 28, 2001. Accepted for publication January 6, 2003.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
L. B. Bacharier, R. C. Strunk, D. Mauger, D. White, R. F. Lemanske Jr., and C. A. Sorkness Classifying Asthma Severity in Children: Mismatch Between Symptoms, Medication Use, and Lung Function Am. J. Respir. Crit. Care Med., August 15, 2004; 170(4): 426 - 432. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. L. Petty, A. L. Parker, M. Abu-Hijleh, and F. D. McCool Term Ambiguity Chest, February 1, 2004; 125(2): 797 - 798. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |